Alector (ALEC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting is scheduled for June 17, 2026, to be held virtually, with voting on director elections, auditor ratification, and executive compensation approval.
The record date for voting is April 20, 2026, with 111,025,187 shares of common stock outstanding.
Proxy materials are primarily distributed electronically, with options for paper copies upon request.
Voting matters and shareholder proposals
Shareholders will vote on electing three Class II directors, ratifying Ernst & Young LLP as auditor for 2026, and an advisory say-on-pay vote for executive compensation.
The board recommends voting FOR all proposals.
Shareholder proposals for the 2027 meeting must be submitted by December 29, 2026, for proxy inclusion, or between February 12 and March 14, 2027, for other business or nominations.
Board of directors and corporate governance
The board consists of eight members, six of whom are independent under Nasdaq rules.
Directors are divided into three staggered classes, with annual elections for one class.
The board is led by an independent chairperson, Louis J. Lavigne, Jr.
Committees include Audit, Compensation, and Corporate Governance and Nominating, each with defined responsibilities and independent membership.
The board emphasizes diversity, regular risk oversight, and executive sessions of independent directors.
Latest events from Alector
- Pivotal FTD-GRN phase III data and AL101 phase II enrollment expected in 2025, backed by strong liquidity.ALEC
Q4 20249 Jul 2026 - ABC platform achieves high-efficiency brain delivery for diverse therapies, advancing CNS drug innovation.ALEC
Status Update9 Jul 2026 - CB-010 and CB-011 prioritized for scalable, durable cell therapies, with cash runway into 2027.ALEC
BofA Securities 2025 Healthcare Conference9 Jul 2026 - Strong cash and late-stage pipeline position support major data readouts and potential AbbVie milestone.ALEC
Q2 20248 Jul 2026 - Late-stage and ABC-enabled therapies for neurodegeneration advance, with key data due 2024–2027.ALEC
Study Update8 Jul 2026 - Net loss narrowed to $22.9M as cost cuts and ABC platform advances extend cash runway through 2027.ALEC
Q1 20267 May 2026 - Virtual annual meeting to elect directors, ratify auditor, and vote on executive pay.ALEC
Proxy filing29 Apr 2026 - ABC platform delivers potent, safe brain-targeted therapies with strong clinical and market potential.ALEC
Corporate presentation26 Mar 2026 - Biotech firm seeks to raise up to $400M for neurodegenerative R&D via flexible securities offering.ALEC
Registration Filing12 Mar 2026